BCDIPLOMA
9.3.2022 23:12:12 CET | Business Wire | Press release
How can organisations protect against fraudulent certifications or fake English assessment test results? How can test takers in Europe receive their TOEIC ® test results in one click? How can test takers in Europe be sure that their test results are certified, tamper-proof and secure? To answer these questions, ETS Global, a subsidiary of ETS, chose to collaborate with BCdiploma, the industry-leading company for the digitisation of academic documents via blockchain technology. In Europe, ETS Global and BCdiploma are working on securing hundreds of thousands of digital TOEIC score reports via blockchain. For ETS Global, this is another step in its digital transformation. Starting from January 2022, TOEIC digital score reports are available in France and will be available across Europe during 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220223005682/en/
The result of this collaboration between these two leading players is a digital TOEIC score report that is :
- Secure: the storage of data on the blockchain makes it impossible to falsify the score report. BCdiploma complies with the strictest data protection regulations. In addition to the blockchain's encryption, BCdiploma adds its own secure, patented algorithms. This way, ETS Global and test takers retain full control over their data, which search engines cannot find or list.
- Universal: BCdiploma adapts to all consultation or sharing standards such as Verifiable Credentials from W3C and EBSI, Open Badges, EDCI, and more.
- User-friendly: available online in one click, this digitised document can be downloaded and sent by email, printed or exported in PDF format. A QR code is added to the document, which the test taker or the recipient of the certification can scan.
- Faster : because results are sent by email, test taker receive their scores faster compared to paper score report shipped by post.
- Streamlined: this digitalisation saves time for universities, schools and training organisations. The sending of results to test takers is automated. As for recruiters, they have access to a certified certificate, avoiding the need for inefficient "fact checking" to verify the authenticity of the document.
- More innovative : for the test taker, sending a secure link or a QR code of a certification guarantees quality and presents a modern picture to recruiters.
- More "carbon compatible"*: TOEIC digital score reports are issued using "Avalanche®", the latest generation and one of the most energy-efficient blockchains. Besides, stopping printing score reports will enable ETS Global to save seven trees/year. And without any paper score report to ship to test takers, ETS Global's carbon footprint will decrease by about 490kg of CO2 /year.
Miguel Membrado, Chief Digital Officer of ETS Global says: "The digitalisation of the education sector has been accelerating for years, and even more so since the start of the pandemic. Being able to offer digital TOEIC® test score reports to all ETS Global stakeholders is an obvious choice. We are delighted to be working with BCdiploma, a leading player in this field. As of today, we are offering this service to our test takers in Europe at no additional cost with the goal that within six months, the use of paper score reports in Europe will decline in favour of digital. This is not a war between digital and paper. Our customers will have the choice, of course. But we are convinced of the benefits of digitalisation to the overall customer experience, which this project perfectly illustrates."
Luc Jarry-Lacombe, CEO of BCdiploma, adds: "Our job as a software publisher is to reinvent a diploma that fits into the Digital Workplace. Better yet, it's about bringing the benefits of the blockchain system to test takers, recruiters, and all training organisations and institutions. 50% to 60% of our costs are dedicated to R&D, which enables us to deliver an impeccable service with the latest blockchain technologies. We are very happy to collaborate with the ETS Global teams, to offer more than a diploma: a real quality marketing object."
*already available in France. Deployment in Europe in 2022
About BCdiploma
BCdiploma has been trusted by more than 120 institutions, universities, and businesses in 18 countries. Our patented technology takes advantage of the latest blockchain and distributed storage technologies to deliver a high value Digital Credentials service. Our team brings to institutions a recognised expertise to succeed in their digital transformation projects. https://www.bcdiploma.com/en
About ETS Global
ETS Global B.V., a wholly owned subsidiary of ETS, is the international arm of ETS. At ETS Global B.V., we bring expertise to educational and business communities around the world, including companies, language schools, academic institutions and public service organisations. ETS Global serves 80 countries and offers a range of ETS products, services and learning solutions. https://www.etsglobal.org/fr/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005682/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom